glypican-3-chimeric antigen receptor-gamma delta T cells + mesothelin-chimeric antigen receptor-gamma delta T cells

This experimental cell therapy consists of a combination of two distinct populations of genetically engineered gamma delta (γδ) T cells, one expressing a chimeric antigen receptor (CAR) targeting glypican-3 (GPC3) and the other expressing a CAR targeting mesothelin (MSLN). Unlike conventional alpha-beta (αβ) T cells, γδ T cells recognize tumor cells in a Major Histocompatibility Complex (MHC)-independent manner, which allows them to target a broader range of antigens and potentially reduces the risk of graft-versus-host disease (GvHD). Glypican-3 is an oncofetal protein that is highly expressed in hepatocellular carcinoma and other solid tumors, while mesothelin is a cell surface glycoprotein overexpressed in cancers such as mesothelioma, pancreatic cancer, and lung cancer. By co-administering these two populations, the therapy aims to address tumor antigen heterogeneity and minimize the risk of immune escape, common hurdles in treating solid malignancies. This approach is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors expressing either GPC3 or mesothelin.

Other names

GPC3-targeted CAR-gamma delta T cells + mesothelin-targeted CAR-gamma delta T cellsGPC3/Mesothelin-CAR-γδT cellsGPC3-CAR-γδ T cells + MSLN-CAR-γδ T cells